Moreover, after being treated with the HRMTF NPs, the intratumoral helper T cells (CD3+CD4+) and cytotoxic T cells (CD3+CD8+) were both largely increased relative to those in the control group (Fig. S17), demonstrating that the HRMTF NPs could finally stimulate the local immune system for cancer therapy. This evidence concerns the gene CD8A and cancer.